Somewhat Positive Press Coverage Somewhat Unlikely to Affect CONMED (CNMD) Stock Price

News coverage about CONMED (NASDAQ:CNMD) has trended somewhat positive on Saturday, according to Accern. The research firm identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. CONMED earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave media coverage about the medical technology company an impact score of 46.4842376893151 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

CONMED (NASDAQ:CNMD) opened at $56.49 on Friday. The company has a market cap of $1,557.59, a P/E ratio of 100.88, a P/E/G ratio of 3.19 and a beta of 0.66. CONMED has a 12 month low of $39.74 and a 12 month high of $56.98. The company has a quick ratio of 1.49, a current ratio of 2.56 and a debt-to-equity ratio of 0.84.

CONMED (NASDAQ:CNMD) last issued its quarterly earnings data on Thursday, November 2nd. The medical technology company reported $0.42 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.01. The company had revenue of $190.10 million during the quarter, compared to the consensus estimate of $187.13 million. CONMED had a net margin of 1.99% and a return on equity of 8.40%. CONMED’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.41 earnings per share. analysts forecast that CONMED will post 1.86 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 5th. Investors of record on Friday, December 15th were paid a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 1.42%. The ex-dividend date was Thursday, December 14th. CONMED’s dividend payout ratio (DPR) is 142.86%.

Several research firms have recently weighed in on CNMD. Zacks Investment Research raised shares of CONMED from a “hold” rating to a “buy” rating and set a $60.00 price target for the company in a research note on Tuesday, January 9th. Piper Jaffray Companies reaffirmed a “hold” rating and set a $46.00 price target on shares of CONMED in a research note on Friday, November 3rd. Needham & Company LLC reaffirmed a “buy” rating and set a $58.00 price target on shares of CONMED in a research note on Friday, November 17th. BidaskClub downgraded shares of CONMED from a “sell” rating to a “strong sell” rating in a research note on Wednesday, December 27th. Finally, KeyCorp reaffirmed a “hold” rating on shares of CONMED in a research note on Friday, November 3rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $53.00.

In related news, CFO Luke A. Pomilio sold 12,429 shares of the business’s stock in a transaction that occurred on Tuesday, November 7th. The shares were sold at an average price of $50.63, for a total value of $629,280.27. Following the completion of the transaction, the chief financial officer now owns 45,486 shares of the company’s stock, valued at $2,302,956.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Luke A. Pomilio sold 10,020 shares of the business’s stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $53.57, for a total transaction of $536,771.40. Following the completion of the transaction, the executive vice president now directly owns 44,472 shares of the company’s stock, valued at approximately $2,382,365.04. The disclosure for this sale can be found here. Insiders sold 51,812 shares of company stock valued at $2,654,756 in the last three months. 2.62% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.com-unik.info/2018/01/20/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-conmed-cnmd-stock-price.html.

About CONMED

CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.

Insider Buying and Selling by Quarter for CONMED (NASDAQ:CNMD)

Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit